(1.20%) 5 070.55 points
(0.69%) 38 504 points
(1.59%) 15 697 points
(0.00%) $83.36
(1.27%) $1.835
(-0.37%) $2 333.50
(-0.17%) $27.32
(-0.41%) $919.00
(-0.06%) $0.934
(-0.08%) $10.89
(-0.05%) $0.803
(-0.01%) $93.18
@ $2.49
Issued: 13 Feb 2024 @ 15:29
Return: 12.45%
Previous signal: Feb 13 - 09:30
Previous signal:
Return: 0.81 %
Live Chart Being Loaded With Signals
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration...
Stats | |
---|---|
Today's Volume | 6.55M |
Average Volume | 2.52M |
Market Cap | 420.92M |
EPS | $0 ( 2024-03-12 ) |
Next earnings date | ( $-0.0700 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.50 |
ATR14 | $0.00900 (0.32%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-19 | Duarte Ira | Buy | 3 874 | Common Stock |
2024-04-19 | Duarte Ira | Sell | 1 122 | Common Stock |
2024-04-19 | Duarte Ira | Sell | 3 874 | Restricted Stock Units |
2024-04-19 | Forbes William P | Buy | 3 874 | Common Stock |
2024-04-19 | Forbes William P | Sell | 3 874 | Restricted Stock Units |
INSIDER POWER |
---|
66.39 |
Last 96 transactions |
Buy: 15 032 989 | Sell: 3 241 807 |
Volume Correlation
Heron Therapeutics Inc Correlation
10 Most Positive Correlations | |
---|---|
TTGT | 0.894 |
TFFP | 0.891 |
RMRM | 0.888 |
VSTA | 0.884 |
TLGT | 0.881 |
ARVN | 0.881 |
BIOL | 0.88 |
GAINL | 0.875 |
PAIC | 0.875 |
WISA | 0.875 |
10 Most Negative Correlations | |
---|---|
BOCH | -0.901 |
NETE | -0.9 |
AMRB | -0.894 |
MMAC | -0.888 |
SHSP | -0.886 |
VLYPO | -0.877 |
SEDG | -0.866 |
IBEX | -0.864 |
SLGN | -0.856 |
RNLC | -0.854 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Heron Therapeutics Inc Correlation - Currency/Commodity
Heron Therapeutics Inc Financials
Annual | 2023 |
Revenue: | $127.04M |
Gross Profit: | $61.94M (48.75 %) |
EPS: | $-0.800 |
Q4 | 2023 |
Revenue: | $34.23M |
Gross Profit: | $24.35M (71.12 %) |
EPS: | $-0.0714 |
Q3 | 2023 |
Revenue: | $31.43M |
Gross Profit: | $13.23M (42.08 %) |
EPS: | $-0.170 |
Q2 | 2023 |
Revenue: | $31.76M |
Gross Profit: | $11.60M (36.53 %) |
EPS: | $-0.350 |
Financial Reports:
No articles found.
Heron Therapeutics Inc
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators